Clinical Trial Update: Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating efficacy and safety of a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for anemia in incident dialysis patients and a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia in Incident Dialysis Patients
• End-stage Renal Disease

Snippet

Sponsor: Second Xiangya Hospital of Central South University | Conditions: Anemia in Incident Dialysis Patients | Phase 4 | Status: UNKNOWN